<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Midlife elevated blood pressure and <z:hpo ids='HP_0000822'>hypertension</z:hpo> contribute to the development of <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) and overall <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We sought to estimate whether <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitors</z:chebi> (ACE-Is) reduced the risk of developing mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (MCI) in cognitively <z:mpath ids='MPATH_458'>normal</z:mpath> individuals </plain></SENT>
<SENT sid="2" pm="."><plain>In the Italian Longitudinal Study on Aging, we evaluated 1,445 cognitively <z:mpath ids='MPATH_458'>normal</z:mpath> individuals treated for <z:hpo ids='HP_0000822'>hypertension</z:hpo> but without <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> from a population-based sample from eight Italian municipalities with a 3.5-year follow-up </plain></SENT>
<SENT sid="3" pm="."><plain>MCI was diagnosed with current clinical criteria </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000726'>Dementia</z:hpo>, AD, and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> were diagnosed based on <z:chebi fb="4" ids="38624">DSM</z:chebi>-IIIR criteria, NINCDS-ADRDA criteria, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-10 codes </plain></SENT>
<SENT sid="5" pm="."><plain>Among 873 <z:hpo ids='HP_0000822'>hypertension</z:hpo>-treated cognitively <z:mpath ids='MPATH_458'>normal</z:mpath> subjects, there was no significant association between continuous exposure to <z:hpo ids='HP_0000001'>all</z:hpo> ACE-Is and risk of incident MCI compared with other <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi> [hazard ratio (HR), 0.45, 95% confidence interval (CI), 0.16-1.28] </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="3380">Captopril</z:chebi> exposure alone did not significantly modify the risk of incident MCI (HR, 1.80, 95% CI, 0.39-8.37) </plain></SENT>
<SENT sid="7" pm="."><plain>However, the enalapril sub-group alone (HR, 0.17, 95% CI, 0.04 -0.84) or combined with the <z:chebi fb="0" ids="43755">lisinopril</z:chebi> sub-group (HR, 0.27, 95% CI, 0.08-0.96), another ACE-I structurally related to enalapril and with similar potency, were associated with a reduced risk of incident MCI </plain></SENT>
<SENT sid="8" pm="."><plain>Study duration exposure to ACE-Is as a "class" was not associated with incident MCI in older hypertensive adults </plain></SENT>
<SENT sid="9" pm="."><plain>However, within-class differences linked to different chemical structures and/or drug potencies may exist, with a possible effect of the enalapril and <z:chebi fb="0" ids="43755">lisinopril</z:chebi> sub-groups in reducing the risk of incident MCI </plain></SENT>
</text></document>